In fact, patients with NAFLD and MetS had the lowest whole efflux capacity, 7.4% lower than that observed in patients without MetS and 22% lower than that observed in PNPLA3-driven NAFLD group. The gene discussed is PNPLA3; the disease is metabolic syndrome.